EGFR and central nervous system cancer: Using R2, we analyzed the annotated FRENCH GBM cohort and found that the expression of TP73-AS1 is associated with the more aggressive gliomas as its expression is lower in tumors carrying an IDH1 mutation, as compared with tumors with wild-type (wt) IDH1 (Fig. 1b) and is higher in EGFR-amplified glioma tumors (Fig. 1b), both of which are more aggressive gliomas.